Companies to watch for potential M&As in 2024

Analysts predict there will be more than $40 billion in annual revenue at risk due to pharma LOE over the next five years, affecting key drugs owned by almost all of the big players, she said. In addition to that, in Bardon’s view several biotechs have achieved a level of success needed to graduate from startups to the prime time category, meaning they have the financial heft to begin making acquisitions of their own.